Heron Therapeutics, Inc. (HRTX) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Heron Therapeutics is a commercial-stage biotechnology company focused on acute care and oncology products, including ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. The company operates as an accelerated filer on the Nasdaq Capital Market.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Net Product Sales | $37.7 million | $37.2 million | $72.4 million | $76.1 million |
| Gross Profit | $26.1 million | $27.3 million | $50.2 million | $57.8 million |
| Gross Margin | 69.3% | 73.5% | 69.3% | 75.9% |
| Net Loss | $(5.5) million | $(2.4) million | $(13.6) million | $0.3 million (Income) |
| Operating Cash Flow | N/A | N/A | $(3.8) million | $(19.7) million |
| Cash & Investments | $42.7 million (as of June 30, 2026) | |||
| Total Debt (Carrying Value) | $142.7 million (Working Capital Facility + Convertible Notes) |
Material Changes vs. Prior Period
- Revenue Mix Shift: Acute care sales (ZYNRELEF, APONVIE) increased 43.9% QoQ, driven by market share gains. Conversely, oncology sales (CINVANTI, SUSTOL) decreased 15.9% QoQ due to competitive pressure.
- Margin Compression: Gross margin declined from 73.5% to 69.3% due to increased inventory reserves/write-offs ($1.0 million in Q2) and higher unit costs.
- Expense Volatility: Sales and marketing expenses rose 22.3% QoQ due to headcount increases and ZYNRELEF marketing. General and administrative expenses dropped 22.1% QoQ, primarily due to reduced legal fees and the termination of the San Diego lease.
- Interest Expense: Other expense, net increased significantly (from $0.7M to $3.4M QoQ) due to higher interest costs from debt refinancing completed in 2025.
Guidance, Outlook, Risks, and Unusual Items
- Product Discontinuation: The company notified the FDA on June 15, 2026, that SUSTOL will no longer be available for sale as of September 30, 2026.
- Debt Covenant Waiver: On August 7, 2026, the company entered into a Fourth Amendment to its Working Capital Facility Agreement. This waived minimum revenue and EBITDA covenants for Q2 2026 but required a $17.5 million prepayment of principal and eliminated future availability of $40 million in tranches.
- Patent Litigation: On June 1, 2026, a court ruled that certain CINVANTI patents (Nos. 12,115,255 and 12,290,520) were invalid and other claims were not infringed in a case against Azurity. The company has appealed this decision. This poses a significant risk to CINVANTI's exclusivity.
- Nasdaq Compliance: The company received a notice on June 25, 2026, regarding failure to meet the $1.00 minimum bid price requirement. It has 180 days (until December 22, 2026) to regain compliance.
- Strategic Review: Management is considering strategic alternatives as of August 10, 2026, with no assurance of a transaction.
Investor Verification Checklist
- Verify the status of the August 7, 2026 debt amendment and the company's ability to meet the revised covenants effective August 31, 2026.
- Monitor the appeal of the Azurity patent ruling and its potential impact on CINVANTI revenue projections.
- Confirm the company's plan to regain Nasdaq compliance before the December 22, 2026 deadline.
- Assess the financial impact of the SUSTOL discontinuation on Q3 and Q4 2026 revenue.
- Review the progress of the strategic alternatives review announced in August 2026.